Status:

COMPLETED

Probiotic on Atopic Dermatitis in Infant

Lead Sponsor:

Glac Biotech Co., Ltd

Conditions:

Atopic Dermatitis

Eligibility:

All Genders

1-3 years

Phase:

NA

Brief Summary

The clinical trial will be carried out in China Medical University Hospital. The overall plan is a double-blind trial. All recruited 1-3 years old atopic dermatitis (AD) patients are divided into two ...

Eligibility Criteria

Inclusion

  • Subjects were between 1 and 3 years old.
  • For patients diagnosed with atopic dermatitis by a professional physician and the EASI score is greater than 10, the type and frequency of drugs used during the experiment should be recorded.
  • The subject's parents agree to join the trial and sign the informed consent form.

Exclusion

  • The patient who has a history of allergic reactions, or the use of other highly sensitive or contraindicated drugs (allergy to antibiotics or antipyretics).
  • The patient who has taken oral immunosuppressants and systemic steroids within the past 2 weeks.
  • The patient who has consumed probiotic-related products (including drops, lozenges, capsules, powder or yogurt) within the past 1 month.
  • The patient who has participated in other clinical studies within the past 1 month.
  • The patient who has received immunotherapy within the past 1 year.
  • The patient who suffering from major diseases (with a IC card for severe illness), congenital diseases.
  • The patient who is not suitable to participate in the trial as assessed by the professional physician.

Key Trial Info

Start Date :

September 23 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 28 2025

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT05286047

Start Date

September 23 2022

End Date

May 28 2025

Last Update

November 26 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Glac Biotech Co., Ltd.

Tainan, Taiwan, 74442